75 related articles for article (PubMed ID: 38665913)
1. Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy.
Jin SX; Liu BN; Ji HJ; Wu JR; Li BL; Gao XL; Li N; Zheng ZD; Du C
Support Care Cancer; 2024 May; 32(6):370. PubMed ID: 38776028
[TBL] [Abstract][Full Text] [Related]
2. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.
Tang W; Li C; Huang D; Zhou S; Zheng H; Wang Q; Zhang X; Fu J
Cancer Biol Ther; 2024 Dec; 25(1):2358551. PubMed ID: 38813753
[TBL] [Abstract][Full Text] [Related]
3. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
JAMA Oncol; 2024 May; ():. PubMed ID: 38780929
[TBL] [Abstract][Full Text] [Related]
4. Muscle-origin creatinine-cystatin C ratio is an osteoporosis marker in individuals with normal renal function: evidence from observational and Mendelian randomization analysis.
He P; Yang YQ; Wang H; Zhang YQ; Gu YN; Hong CC; Bo L; Deng FY; Lei SF
Front Endocrinol (Lausanne); 2024; 15():1325320. PubMed ID: 38836225
[TBL] [Abstract][Full Text] [Related]
5. Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer.
Liu Y; Chen W; Ruan R; Zhang Z; Wang Z; Guan T; Lin Q; Tang W; Deng J; Wang Z; Li G
J Transl Med; 2024 May; 22(1):438. PubMed ID: 38720336
[TBL] [Abstract][Full Text] [Related]
6. Association of body composition and survival in patients with locally advanced breast cancer: a historical cohort study.
Pakdee W; Laohawiriyakamol T; Tanutit P; Laohawiriyakamol S; Liabsuetrakul T
Acta Radiol; 2024 Jun; 65(6):575-587. PubMed ID: 38591936
[TBL] [Abstract][Full Text] [Related]
7. Association Between Body Composition and Survival in Patients With Gastroesophageal Adenocarcinoma: An Automated Deep Learning Approach.
Jung M; Diallo TD; Scheef T; Reisert M; Rau A; Russe MF; Bamberg F; Fichtner-Feigl S; Quante M; Weiss J
JCO Clin Cancer Inform; 2024 Apr; 8():e2300231. PubMed ID: 38588476
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
[TBL] [Abstract][Full Text] [Related]
10. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
11. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer.
Lee MW; Jeon SK; Paik WH; Yoon JH; Joo I; Lee JM; Lee SH
J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):735-745. PubMed ID: 38332658
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
McManus HD; Zhang D; Schwartz FR; Wu Y; Infield J; Ho E; Armstrong AJ; George DJ; Kruse D; Gupta RT; Harrison MR
Clin Genitourin Cancer; 2023 Dec; 21(6):e429-e437.e2. PubMed ID: 37271698
[TBL] [Abstract][Full Text] [Related]
14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
15. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.
Kim YY; Lee J; Jeong WK; Kim ST; Kim JH; Hong JY; Kang WK; Kim KM; Sohn I; Choi D
Gastric Cancer; 2021 Mar; 24(2):457-466. PubMed ID: 32970267
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
